Sun Pharmaceutical Industries has entered into a global licensing agreement
with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related
to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma's
specialty focus areas.
Under the terms of the license agreement, Sun Pharma gets exclusive global license for the said
patents and any other future patents covered in the agreement. Sun Pharma will pay CSIR-IICT
upfront and potential development, regulatory and sales milestone payments totaling up to Rs. 240 crore, plus royalties on net sales from commercialization of the products developed using these
patents. Sun Pharma will be responsible for development, regulatory filings, manufacturing and
commercialization of these potential products.
This agreement will facilitate addition of pre-clinical candidates to Sun Pharma's global specialty
pipeline. A successful clinical development of these potential compounds may enable Sun Pharma to
commercialize pharmaceutical products for various therapeutic indications over the long term.